Company intelligence / Profile preview
Medicus Pharma Ltd.
- Ownership
- Public · MDCX
- Development stage
- Other
Overview
Medicus Pharma’s lead program SkinJect has completed a successful Phase I trial demonstrating safety and preliminary efficacy for basal cell carcinoma. The ongoing randomized controlled Phase II trial has shown over a 60% clinical clearance rate at interim analysis. The company recently secured $7M in funding to support these trials and plans to expand its pipeline through acquisitions such as the announced deal with Antev Ltd., which brings late-stage programs targeting prostate cancer and acute urinary retention[6][7].
- Therapeutic areas
- Men's HealthOncology
- Modalities
- Small molecules (e.g., doxorubicin in microneedle array)Drug-device combination (dissolvable microneedle patch)Peptide-based GnRH antagonist (Teverelix, pending acquisition)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Financials
- Market cap
- $2.6M
- Total revenue
- $0
- Enterprise value
- $7.2M
Beyond the preview
Go deeper on Medicus Pharma Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medicus Pharma Ltd..